Australia was involved in the randomised Napoli 3 trial which basically had folfirinox arm (just used different Irinotecan preparation), so it doesn’t suggest any concerns with this combination, otherwise no Australian sites would have joined. As duke says, for better performance status patient , folfirinox will be a SOC in Australia and most oncologists know how to manage the toxicities.
Ann: AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL, page-8
Add to My Watchlist
What is My Watchlist?
